Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing therapeutics for aesthetic and dermatological conditions, specifically androgenetic alopecia. The company is developing VDPHL01, an oral, extended-release formulation of minoxidil designed to treat hair loss in both men and women. VDPHL01 is intended to offer a non-hormonal alternative to current treatments, aiming to address limitations in onset of action, consistency, and tolerability associated with existing options. The company is conducting registration-directed clinical trials, including Phase 2/3 and Phase 3 studies in male and female patients, to support a New Drug Application submission to the FDA. Veradermics utilizes a proprietary formulation technology to optimize the pharmacokinetic profile of minoxidil, maximizing hair growth efficacy while minimizing cardiac side effects. The company’s pipeline is centered on this single lead asset, with a focus on establishing a new standard of care for chronic hair loss therapy.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ir.veradermics.com
Sector Healthcare IR page ir.veradermics.com
Tags
dermatology, hair loss, alopecia, minoxidil, oral therapeutics, extended-release formulation, clinical-stage, aesthetic medicine, VDPHL01
Press page —

Metrics

Valuation  
Market cap $ 6.344B
Market cap (USD) $ 6.344B
P/E -1.34
PEG —
P/BV 7.96
P/S —
P/OCF -88.60
P/FCF -88.57
Dividend yield —
Turnover / mcap —
Returns  
ROE 57.8%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025
Assets 152.619M
Net profit -69.995M
Free cash flow -71.626M

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 0.00 4,000
Cash and deposits (USD) 16.3M 53.1M 21.8M
Right-of-use assets (USD) — 0.00 103,000
Cash flow detail
Operating cash flow (USD) — -23.7M -71.6M
Purchases of property, plant and equipment (USD) — 0.00 -24,000
Change in payables (cash effect) (USD) — 646,000 -122,000
Interest paid (cash effect) (USD) — -95,000 0.00
Income taxes paid (cash effect) (USD) — 0.00 0.00
Share-based compensation (USD) — 250,000 1.44M
Free cash flow (OCF - PPE - intangibles) (USD) — -23.7M -71.6M
Income detail
Research and development expense (USD) — 23.3M 62.1M
Total comprehensive income (USD) — -26.5M -69.9M
Comprehensive income to owners (USD) — -26.5M -69.9M
Reported Mar 30, 2026 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years

Company remains on track to deliver topline data from Phase 2/3 Study ‘306’ evaluating VDPHL01 in female pattern hair loss in 1H27

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth in first ever positive Phase 2 trial for an oral treatment for female pattern hair loss in the U.S.

Cash, cash equivalents and marketable securities of $798.4 million as of September 30, 2026, expected to fund operations into 2030 through multiple Phase 3 readouts and potential commercial launch of VDPHL01

NEW HAVEN, Conn.--(BUSINESS WIRE)— Nov. 10, 2026 - Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress.

VDPHL01, a novel orally-administered extended-release minoxidil formulation, demonstrated Target Area Hair Count (TAHC) deepening in twice-daily (BID) and maintenance in once-daily (QD) treatment arms with increases in non-vellus hair counts of 43.9 hairs/cm 2 (BID) and 29.7 hairs/cm2 (QD) from baseline at Month 12

12-month long-term data demonstrated consistency of hair growth across patient-reported outcomes (PRO) with 89.1% (BID) and 79.8% (QD) reporting visible improvement and 68.0% (BID) and 48.4% (QD) of participants reporting ‘much improved’ or ‘improved’ hair coverage

Favorable 12-month long-term safety and tolerability profile remained consistent with previously reported data, with no new safety signals and no adverse event-related study discontinuations observed after an additional 6 months of treatment

These 12-month long-term results combined with previously reported positive topline findings from Part A of Study ‘302’ and ‘304’ reinforce the potential for VDPHL01 to become the first FDA-approved, non-hormonal, oral treatment for the 50 million men with pattern hair loss in the U.S.

Conference call and webcast scheduled for 8:00 a.m.

Veradermics, Incorporated — Regulation FD Disclosure Bull 7 Bear 0 Clinical/regulatory

On October 19, 2026, Veradermics, Incorporated (the “Company”) issued a press release announcing positive topline data from the Phase 3 clinical trial, Study ‘304’ evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation the Company presented on a conference call and webcast held to discuss the Study ‘304’ topline data is furnished as Exhibit 99.2 to this Current Report on Form 8-K, and both are incorporated by reference herein.

Other Events

On October 19, 2026, the Company announced positive topline data from the Phase 3 clinical trial, Study ‘304’ evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. Study ‘304’ is a multi-center, randomized, placebo-controlled study evaluating clinical efficacy, safety, and tolerability in 536 enrolled patients who were randomized to receive either VDPHL01 8.5mg once daily (“QD”), VDPHL01 8.5mg twice daily (“BID”) or placebo.

Prompts

Veradermics, Incorporated (ticker MANE), listed in United States.

ETFs Holding Veradermics, Incorporated

ETF Weight in ETF Shares Market value As of
LFSC 2.87% 36,765 $ 3.618M Aug 31, 2026
SCDS 0.43% 312 $ 39.2K Nov 17, 2026
JGRO 0.23% 166,711 $ 20.946M Nov 17, 2026
MSSM 0.00% 320 $ 31.491K Aug 31, 2026